APA (7th ed.) Citation

Zhuravleva, M. V., Gagarina, Y. V., & Marin, T. V. (2025). Cost-effectiveness of using sodium-glucose cotransporter type 2 inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program in patients with chronic kidney disease and resistant hypertension. «FIRMA «SILICEA» LLC.

Chicago Style (17th ed.) Citation

Zhuravleva, M. V., Yu. V. Gagarina, and T. V. Marin. Cost-effectiveness of Using Sodium-glucose Cotransporter Type 2 Inhibitors as a Part of Therapy for Cardiovascular Death Prevention and Achieving the Reduction of Cardiovascular Mortality Indicator of the Healthcare Development State Program in Patients with Chronic Kidney Disease and Resistant Hypertension. «FIRMA «SILICEA» LLC, 2025.

MLA (9th ed.) Citation

Zhuravleva, M. V., et al. Cost-effectiveness of Using Sodium-glucose Cotransporter Type 2 Inhibitors as a Part of Therapy for Cardiovascular Death Prevention and Achieving the Reduction of Cardiovascular Mortality Indicator of the Healthcare Development State Program in Patients with Chronic Kidney Disease and Resistant Hypertension. «FIRMA «SILICEA» LLC, 2025.